AbbVie's Born -- What Now? Motley Fool Multiple sclerosis treatment daclizumab, a partnership project with Biogen Idec (NASDAQ: BIIB ) , should report data sometime next year. Brian Orelli discussed the mid-stage trial results containing promising efficacy better than Teva's (NYSE: TEVA ) ... |
